{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:34:43Z","timestamp":1794411283893,"version":"4.9.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.euroneuro.2019.06.008","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T04:33:49Z","timestamp":1561610029000},"page":"971-985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"title":["Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone"],"prefix":"10.1016","volume":"29","author":[{"given":"Filippo","family":"Corponi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Bitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pallanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2019.06.008_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.genhosppsych.2017.05.002","article-title":"Efficacy of lurasidone in the treatment of agitation: a post hoc analysis of five short-term studies in acutely ill patients with schizophrenia","volume":"47","author":"Allen","year":"2017","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0004","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders, 5th ed, Washington, DC.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1176\/ps.2007.58.1.85","article-title":"Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders","volume":"58","author":"Baldessarini","year":"2007","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0006","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4088\/JCP.14m09081","article-title":"Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study","volume":"76","author":"Calabrese","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0007","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.euroneuro.2017.06.013","article-title":"Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder","volume":"27","author":"Calabrese","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0008","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.neuropharm.2013.01.023","article-title":"Effects of lurasidone in behavioral models of depression. Role of the 5-HT(7) receptor subtype","volume":"70","author":"Cates","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clinthera.2015.11.013","article-title":"Lurasidone dose response in bipolar depression: a population Dose-response analysis","volume":"38","author":"Chapel","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3371\/CSRP.6.2.5","article-title":"Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?","volume":"6","author":"Citrome","year":"2012","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0011","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2019.06.008_bib0012","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4088\/JCP.13049su1c.04","article-title":"Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains","volume":"75","author":"Citrome","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0013","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/ijcp.12752","article-title":"The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out","volume":"69","author":"Citrome","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0014","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ijcp.12714","volume":"69","author":"Citrome","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","article-title":"Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study","volume":"27","author":"Citrome","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0016","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4088\/JCP.15m10192","article-title":"The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials","volume":"77","author":"Citrome","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0017","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jad.2013.10.040","article-title":"Clinical assessment of lurasidone benefit and risk in the treatment of bipolar i depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"155","author":"Citrome","year":"2014","journal-title":"J Affect Disord"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0018","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1017\/S109285291300093X","article-title":"Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study","volume":"19","author":"Citrome","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0019","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/YIC.0000000000000189","article-title":"Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials","volume":"32","author":"Corponi","year":"2017","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0020","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","volume":"172","author":"Correll","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0021","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14737175.2016.1174577","article-title":"ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes","volume":"16","author":"Davis","year":"2016","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0022","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0924-9338(15)30197-8","article-title":"Cariprazine in negative symptoms of schizophrenia: post-hoc analyses of a fixed-dose phase III, randomized, double-blind, placebo-and active-controlled trial","volume":"30","author":"Debelle","year":"2015","journal-title":"European Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0023","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0024","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.schres.2016.06.030","article-title":"Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"176","author":"Durgam","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"31","author":"Durgam","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0026","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0027","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","author":"Durgam","year":"2015","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0028","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/YIC.0000000000000187","article-title":"Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II\/III randomized, double-blind, placebo-controlled studies","volume":"32","author":"Earley","year":"2017","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jad.2017.09.040","article-title":"Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder","volume":"226","author":"Earley","year":"2018","journal-title":"J Affect Disord"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0030","article-title":"Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data","author":"Earley","year":"2018","journal-title":"Schizophr Res."},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0031","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mehy.2013.03.013","article-title":"A serotonin hypothesis of schizophrenia","volume":"80","author":"Eggers","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0032","first-page":"321","article-title":"Quality of life enjoyment and satisfaction Questionnaire: a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0033","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/JCP.0000000000000678","article-title":"Efficacy of brexpiprazole as adjunctive treatment in major depressive disorder with irritability: post hoc analysis of 2 pivotal clinical studies","volume":"37","author":"Fava","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0034","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1517\/14656566.6.12.2091","article-title":"Aripiprazole","volume":"6","author":"Fleischhacker","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0035","first-page":"11","article-title":"Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"20","author":"Fleischhacker","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0036","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.euroneuro.2014.11.010","article-title":"The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder","volume":"25","author":"Fountoulakis","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0037","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/1745017901410010042","article-title":"Misdiagnosed hypomanic symptoms in patients with treatment-resistant major depressive disorder in Italy: results from the improve study","volume":"10","author":"Francesca","year":"2014","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0038","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.schres.2015.06.027","article-title":"Antipsychotic binding to the dopamine-3 receptor in humans: a PET study with [(11)C]-(+)-PHNO","volume":"168","author":"Girgis","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0039","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archgenpsychiatry.2009.43","article-title":"The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO","volume":"66","author":"Graff-Guerrero","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00210-012-0806-3","article-title":"Dopamine D(3) receptor antagonism\u2013still a therapeutic option for the treatment of schizophrenia","volume":"386","author":"Gross","year":"2013","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0041","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0042","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.schres.2015.06.008","article-title":"Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study","volume":"166","author":"Harvey","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0043","first-page":"79","article-title":"A Randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2\u00a0mg\/d as adjunctive treatment of adults with major depressive disorder","author":"Hobart","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0044","unstructured":"Intra-Cellular Therapies, 2018. Intra-Cellular therapies announces FDA acceptance of new drug application for lumateperone for the treatment of schizophrenia. Available at:https:\/\/globenewswire.com\/news-release\/2018\/12\/11\/1664993\/0\/en\/Intra-Cellular-Therapies-Announces-FDA-Acceptance-of-New-Drug-Application-for-Lumateperone-for-the-Treatment-of-Schizophrenia.htmlAccessed 28 December 2018."},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0046","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0047","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an International, phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0048","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0049","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jad.2017.08.040","article-title":"The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: a 16-week open-label study","volume":"225","author":"Ketter","year":"2018","journal-title":"J Affect Disord"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/da.22479","article-title":"Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study","volume":"33","author":"Ketter","year":"2016","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0051","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0052","first-page":"18","article-title":"Effects of adjunctive brexpiprazole on sleep disturbances in patients with major depressive disorder: an Open-Label, Flexible-Dose, exploratory study","volume":"5","author":"Krystal","year":"2016","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0053","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br Med Bull"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0054","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0056","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0057","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80\u00a0mg\/day and 160\u00a0mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0058","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0059","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eurpsy.2014.08.001","article-title":"Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies","volume":"30","author":"Loebel","year":"2015","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0061","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0062","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.4088\/JCP.16m10698","article-title":"Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study","volume":"77","author":"Loebel","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0063","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.114.213819","article-title":"Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0064","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0065","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study","volume":"168","author":"Meltzer","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0066","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/bdi.12534","article-title":"Methodological recommendations for cognition trials in bipolar disorder by the international society for bipolar disorders targeting cognition task force","volume":"19","author":"Miskowiak","year":"2017","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0067","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","article-title":"Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO","volume":"131","author":"Mizrahi","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0068","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0069","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S1092852914000285","article-title":"Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies","volume":"20","author":"Nasrallah","year":"2015","journal-title":"CNS Spectr"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0070","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study","volume":"47","author":"Nasrallah","year":"2013","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0071","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"Nemeth","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0072","doi-asserted-by":"crossref","DOI":"10.2217\/cer-2018-0016","article-title":"Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis","author":"Ng-Mak","year":"2018","journal-title":"J Comp Eff Res."},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0073","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study","volume":"225","author":"Ogasa","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0074","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1176\/appi.ajp.2013.13020185","article-title":"The international society for bipolar disorders (ISBD) task force report on antidepressant use in bipolar disorders","volume":"170","author":"Pacchiarotti","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0075","first-page":"870","article-title":"Unmet needs in schizophrenia","volume":"16","author":"Pompili","year":"2017","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0076","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.04.008","article-title":"Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder","volume":"132","author":"Potkin","year":"2011","journal-title":"Schizophr Res"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2019.06.008_bib0077","first-page":"52","article-title":"PM418. Efficacy of lurasidone in patients with schizophrenia with prominent positive Symptoms: a pooled analysis of shortterm placebo-controlled studies","volume":"19","author":"Potkin","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0078","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.2338","article-title":"Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies","volume":"28","author":"Preskorn","year":"2013","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0079","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/0269881118760661","article-title":"Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: efficacy and safety","volume":"32","author":"Romeo","year":"2018","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0080","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jad.2014.11.018","article-title":"Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial","volume":"174","author":"Sachs","year":"2015","journal-title":"J Affect Disord"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0081","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40263-012-0026-x","article-title":"Lurasidone: in the treatment of schizophrenia","volume":"27","author":"Sanford","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0082","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000358808","article-title":"Mixed depression: clinical features and predictors of its onset associated with antidepressant use","volume":"83","author":"Sani","year":"2014","journal-title":"Psychother Psychosom"},{"issue":"Suppl 3","key":"10.1016\/j.euroneuro.2019.06.008_bib0083","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0084","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1600-0447.2008.01324.x","article-title":"Sub-threshold manic symptoms in recurrent major depressive disorder are a marker for poor outcome","volume":"119","author":"Smith","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0085","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0086","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0087","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0088","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pnpbp.2017.05.002","article-title":"Lurasidone in post-menopausal females with major depressive disorder with mixed features: post-hoc analysis of a placebo-controlled trial","volume":"78","author":"Sramek","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0089","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4088\/JCP.12m08084","article-title":"Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study","volume":"74","author":"Stahl","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpsychires.2016.03.012","article-title":"Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts","volume":"78","author":"Suppes","year":"2016","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0091","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1176\/appi.ajp.2015.15060770","article-title":"Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study","volume":"173","author":"Suppes","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0092","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1017\/S1092852917000232","article-title":"Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis","volume":"22","author":"Swann","year":"2017","journal-title":"CNS Spectr"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0093","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0269881115620460","article-title":"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"30","author":"Tandon","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0094","series-title":"The maudsley prescribing guidelines in psychiatry","author":"Taylor","year":"2018"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0095","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/acps.12343","article-title":"Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis","volume":"130","author":"Taylor","year":"2014","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0096","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.14m09688","article-title":"Efficacy and safety of adjunctive brexpiprazole 2\u00a0mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants","volume":"76","author":"Thase","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0097","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4088\/JCP.14m09689","article-title":"Adjunctive brexpiprazole 1 and 3\u00a0mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study","volume":"76","author":"Thase","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0098","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1017\/S1092852917000074","article-title":"Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study","volume":"22","author":"Tsai","year":"2017","journal-title":"CNS Spectr"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0099","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/acps.12896","article-title":"Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines","volume":"138","author":"Verdolini","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0100","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.euroneuro.2015.08.020","article-title":"Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II\/III trials","volume":"25","author":"Vieta","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0102","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pbb.2014.06.008","article-title":"Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors","volume":"124","author":"Yoshimi","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0103","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.euroneuro.2014.12.014","article-title":"Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator","volume":"25","author":"Yoshimi","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0104","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.euroneuro.2019.06.008_bib0105","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19302664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X19302664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:53:56Z","timestamp":1760378036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X19302664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0924977X19302664"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.06.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2019.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}